



Contact: Ralph Barry, Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: rbarry@aegisthera.com

Aegis Therapeutics' Intravail® Technology Selected as Winner in *Pharmaceutical Technology's* "Innovations in Pharma Science Awards" for 2008

SAN DIEGO, CA January 6, 2009/MarketWire/-- Aegis Therapeutics LLC's Intravail® transmucosal absorption enhancement technology has been selected as a winner in *Pharmaceutical Technology's* "Innovations in Pharma Science Awards". Intravail® excipients make it possible to administer previously injectable-only drugs such as growth hormone, interferon, glucagon, and siRNA drugs through various non-invasive means including metered nasal sprays, flash dissolve buccal tablets, or oral formulations. Intravail® is featured in the December 2008 issue of *Pharmaceutical Technology (Pharm Tech)*. *Pharm Tech* is a peer-reviewed publication serving 38,600 BPA-audited subscribers, the largest circulation in the industry, delivering practical, technical, and business-critical information to decision-makers in the pharmaceutical, biopharmaceutical, and manufacturing fields. It is available in a print version as well as an electronic version which may be accessed at <http://www.pharmtech.com>.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our patented Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal administration route. Intravail® has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our patented ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.

For more information about Aegis, please visit the Aegis website at: <http://www.aegisthera.com>.
